Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
根據最新的財務報表(Form-10K),ABIVAX Société Anonyme 的總資產為 $0,淨損失為 $0
ABVX 的關鍵財務比率是什麼?
ABIVAX Société Anonyme 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
ABIVAX Société Anonyme 的收入按細分市場或地理位置如何劃分?
ABIVAX Société Anonyme 最大收入來源為 Electrical Distribution Systems,在最近的收益報告中收入為 8,818,000,000。就地區而言,North America 是 ABIVAX Société Anonyme 的主要市場,收入為 7,141,000,000。